Madrigal Pharmaceuticals receives notice of allowance for Rezdiffra patent

Madrigal Pharmaceuticals (MDGL) announced that the United States Patent and Trademark Office has issued a Notice of Allowance covering the FDA-approved use of Rezdiffra, the first and only FDA-approved treatment for adults with noncirrhotic MASH with moderate to advanced liver fibrosis. The Notice of Allowance includes claims directed to Rezdiffra’s commercial weight-threshold dosing regimen as prescribed in the FDA-approved label. The U.S. patent scheduled to issue from this application provides protection through Sept. 30, 2044, and will be listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.